

Bausch + Lomb ULTRA® Contact Lenses Receive FDA Approval for Extended Wear Indication

May 02, 2018

LAVAL, Quebec, May 2, 2018 – Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International (NYSE/TSX: VRX), today announced that the U.S. Food and Drug Administration (FDA) has approved the Bausch + Lomb ULTRA® family of contact lenses for extended wear for up to seven days between removals for cleaning and disinfection or disposal of the lens, as recommended by the eye care professional. First introduced in the United States in 2014, Bausch + Lomb ULTRA is the only brand of contact lenses that include MoistureSeal® technology, a patented combination of material and manufacturing process, which helps to maintain 95 percent of lens moisture for a full 16 hours.¹

"Developed in-house by our team of scientists and lens designers, Bausch + Lomb ULTRA lenses help address the needs of today's contact lens patients," said Joseph C. Papa, chairman and CEO, Valeant.

"Bausch + Lomb ULTRA lenses offer an exceptional lens wearing experience, backed by outstanding clinical performance, and now, convenient wear for up to seven days."

Bausch + Lomb ULTRA contact lenses are engineered to provide all-day comfort and consistently clear vision. The family of contact lenses features polyvinylpyrrolidone (PVP) for enhanced wettability, a high oxygen transmissibility level (Dk/t) (i.e. ability of the lens to let oxygen reach the eye), and a low modulus (i.e. the degree of a contact lens material's flexibility or its resistance to being deformed). Bausch + Lomb ULTRA® contact lenses are also available for patients with astigmatism and presbyopia.

"Bausch + Lomb ULTRA contact lenses are a trusted and preferred lens option for my practice and my patients," said Ben Gaddie, O.D., Gaddie Eye Centers, Louisville, KY. "Now with the extended wear indication, I can offer these lenses to patients who prefer a longer wearing schedule as part of their lifestyle."

For more information on Bausch + Lomb ULTRA® contact lenses, visit www.ultracontactlenses.com

Important Safety Information about Bausch + Lomb ULTRA Contact Lenses (Extended Wear)

The risk of microbial keratitis and other potentially vision-threatening adverse events has been shown to be greater among users of extended wear contact lenses than among users of daily wear contact lenses. If a patient experiences eye discomfort, excessive tearing, vision changes, or redness of the eye, the patient should be instructed to immediately remove the lenses and promptly contact his or her eye care practitioner.

About Bausch + Lomb

Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people's eyesight. Our core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and

instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at

www.valeant.com

Forward-looking Statements

This news release may contain forward-looking statements which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Valeant's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

References

- Data on file. Bausch & Lomb Incorporated. Rochester, NY; 2013.

###

Bausch + Lomb ULTRA and MoistureSeal are trademarks of Bausch & Lomb Incorporated or its affiliates.

All other trademarks are the property of their respective owners.

© 2018 Bausch & Lomb Incorporated.

Investor Inquiries

ir@bauschhealth.com

877-281-6642

514-856-3855 (Canada)



[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Media inquiries

Corporate.communications@bauschhealth.com

908-569-3692

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.

©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

